(RTTNews) - Abbott Laboratories (ABT), Wednesday announced that its sensor-based glucose technology, the FreeStyle Libre 3 Plus sensor, is now publicly funded in every province across Canada, meaning more people with diabetes can access the glucose sensor.
The product is now covered under federal plans like Non-Insured Health Benefits and by a majority of employer-sponsored workplace benefits programs.
Luz Herrera, general manager of Abbott's diabetes care business in Canada, commented, "The broad coverage is a clear testament to the deep impact and value of our technology."
ABT is currently trading at $127.66, down 0.15 percent on the New York Stock Exchange.
,
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
